The global pharmaceutical industry has been involved in a period of transformational change over approximately the last decade, moving from traditional product development methods and Pharmaceutical Quality Systems (PQS) towards holistic and patient-risk-based approaches to knowledge and lifecycle management as described by ICH Q8, Q9 and Q10. For the most part, this new focus on science, process control and patient risk has impacted the development and initial process validation expectations for new products, however there are also newly articulated regulatory expectations for “ongoing”, or “continued”, process verification during the entire commercial life of a pharmaceutical product. For many firms, especially small to mid size manufacturers, the most urgent issues in aligning with the new process validation lifecycle are not about new products at all, but rather center around the ongoing verification of existing, or “legacy”, products. Some of the common questions that arise include:
In an attempt to provide a multi-company view of these and other issues, the ISPE PV Team has drafted a paper addressing the concerns of firms attempting to implement the Process Validation Lifecycle generally and the Ongoing Process Verification phase specifically. Led by Senior Quality Managers from industry leading companies, the paper presents perspectives on both company-wide and individual-product strategies. It may be problematic for firms to simply increase all monitoring of all attributes to “statistical” levels, especially if there is not a well developed knowledge base and PQS to support the enhanced monitoring’s implementation. A “roadmap” to implementation may be needed. This paper is intended to help plan that journey for legacy product firms. Download the Process Validation Lifecycle Implementation for Existing (“Legacy”) Products discussion paper today!
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...